Navigation Links
Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay
Date:10/2/2008

tatements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-look
'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
2. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
3. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
4. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
5. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
6. Queens University Chooses Xceeds Ziplex(R) System for Translational Research
7. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
8. The University of Nottingham in the British Midlands Announces Breakthrough in Parkinsons Disease Research
9. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
10. First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan
11. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... EAST SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology ... sites where its Phase I trial of Lixte,s lead compound, ... 5 institutions. John S. Kovach , M.D., ... trial was planned to be completed at a single site. ...
(Date:1/23/2015)... CAPE TOWN, South Africa , Jan. 23, 2015 ... and distributor of personal protective equipment for all forms ... include the flagship Leatt-Brace® neck brace, announced today that ... minicross racing federation, now requires all riders to wear ...
(Date:1/23/2015)... Jan. 23, 2015  Mallinckrodt plc (NYSE: MNK ... approved a share repurchase program. The open-ended authorization permits ... Mallinckrodt plc ordinary shares. "Funding additional ... priorities as we continue to pursue a range of ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... HAMBURG, Germany, Sept. 20, 2011 Weight and height, ... leader for medical measuring and weighing. Now the company ... system integrating modern medical practices and hospital equipment. The ... problems of precise data capture, transmission and interpretation of ...
... Sept. 20, 2011 Valeant Pharmaceuticals International, Inc. ... existing senior secured credit facilities of its wholly ... facilities are guaranteed by the Company.  The proposed ... to consist of a $200 million revolving facility ...
Cached Medicine Technology:seca 360 wireless - The New Era of Measuring and Weighing 2Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities 2
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
(Date:1/22/2015)... IPSWICH, Mass. (PRWEB) January 22, 2015 ... Association (AMA) are expanding their relationship in an effort ... journals around the world. While EBSCO has long made AMA ... as a sales agent for The JAMA Network. ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding ... its latest collection of wedding dresses , and launches a ... the wedding dress on your big day; the wedding gown ... bride wants to find the most suitable wedding dress. Now, ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Aug. 15 ( http://www.amdl.com ),AMDL Inc. (Amex: ... pharmaceuticals with,operations in Shenzhen, Jiangxi and Jilin China, ... chief financial officer Akio Ariura will,host a teleconference ... The call is scheduled for Tuesday, August 19, ...
... Neuroblastoma is one of the most devastating diagnoses a ... old when the disease is detected, most often by ... By then, the disease has often reached an advanced ... of the children in whom it develops, despite aggressive ...
... a,statement of Betsy Ryan, President and CEO, New ... today submitted an application to the,state to convert ... for-profit,company., All New Jerseyans should be concerned ... 2.9 million members, Horizon is the largest,provider of ...
... Aug. 15 The Hereditary Disease Foundation,(HDF) is ... has,approved Xenazine, or tetrabenazine, for the treatment of ... major cause of disability and death in patients ... inconvenience; it can,prevent Huntington,s disease patients from walking, ...
... Organizations Come Together to Promote Health Care Reform as the ... Priority for the Next President and Congress, WASHINGTON, Aug. ... to defeat health care reform in 1993-1994, will be back ... top of the,agenda., Airing throughout the Democratic and Republican ...
... spent more than a few sleepless nights, you,re not ... over 55 -- but you may also be at ... older adults don,t get enough restorative sleep, leading to ... problems and increased rates of depression. Unfortunately, current sleeping ...
Cached Medicine News:Health News:AMDL Announces Teleconference to Discuss Its Second Quarter 2008 Financial Results 2Health News:Experiments could lead to new treatments for neuroblastoma 2Health News:Experiments could lead to new treatments for neuroblastoma 3Health News:NJHA Raises Questions Regarding Horizon's Proposal to Convert to For-Profit Health Insurer 2Health News:'Harry and Louise' Icons Return To Promote Health Care Reform In New Ad 2Health News:A therapy for baby boomers to sleep on 2
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv 500, HME...
... Thermovent® T helps provide protection to the exposed ... and extremely lightweight making it ideal for active ... high rate of heat and moisture recovery, it ... ,All HMEs and filters have ISO standard tapered ...
For use with: , pulmonary function testing , nebulizer compressors , humidifiers , concentrators , proximal pressure lines ...
Medicine Products: